ACM
PHAT icon

AIGH Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

AIGH Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-429,000
Closed -$5.05M – 42
2025
Q3 		$5.05M Buy
+429,000
New +$4.43M 1.42% 23

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

AIGH Capital Management's PHAT Position: Q4 2025 in Review

AIGH Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q4 2025, closing a stake of 429,000 shares — an estimated $5.05M sold.

AIGH Capital Management first reported a position in PHAT in Q3 2025 and held it in 1 quarter. The position peaked at $5.05M in Q3 2025. 172 funds tracked by Wall St. Rank hold PHAT as of Q4 2025.

  • AIGH Capital Management reported no remaining Phathom Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • AIGH Capital Management sold 429,000 Phathom Pharmaceuticals shares in Q4 2025, an estimated $5.05M.
  • AIGH Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • AIGH Capital Management's Phathom Pharmaceuticals position peaked at $5.05M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2025.

Based on AIGH Capital Management's 13F filing for Q4 2025, filed 2 Feb 2026.